SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LemurHouse who wrote (489)3/23/2001 8:09:43 AM
From: D.Austin  Read Replies (1) of 656
 
Hello Andrew
I agree The story is huge.But the other real concern is the
money pouring out of biotechs.P/E's will matter and IMNX just got theirs slashed in half.And as far as a gap back to 15 or 16 real quick is not likely.The gap down is to significant,just the erosion from the 30's to the low 20's was interesting.We may see the averageP/E's of biotechs
back to the 15 or 16 range.

From the Street.Com
The company reported Enbrel sales of $652 million in 2000. Last month, the company issued 2001 sales estimates of $750 million, lower than expected because of production problems.
Production problems or demand problems ?

?sector rotation?maybe
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News